Close Menu

NEW YORK – As clinicians and scientists have worked to understand and control the spread and scope of the SARS-CoV-2 pandemic, molecular testing and serology have emerged as important tools for diagnosing and studying the disease.

Protein-based antigen testing has received relatively less attention, but several companies now have such tests in the works with plans to release them for clinical use within the next several months. Given their rapid turnaround time, ease of use, and amenability to large scale production, these tests could prove valuable for addressing the outbreak.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.